

Elizabeth A Magnuson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6526164/publications.pdf>

Version: 2024-02-01

16
papers

1,336
citations

933447

10
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

1973
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation. <i>Heart</i> , 2022, , heartjnl-2021-320005.	2.9	14
2	Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360 ^o trial. <i>Journal of Medical Economics</i> , 2021, 24, 570-580.	2.1	4
3	Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF ^o TIMI 48 Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006511.	2.2	6
4	Reply. <i>Journal of the American College of Cardiology</i> , 2018, 71, 108.	2.8	1
5	Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	8
6	Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective. <i>Value in Health Regional Issues</i> , 2017, 12, 74-83.	1.2	11
7	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF ^o TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	21
8	Cost-Effectiveness of Long-Term ^o Ticagrelor in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 527-538.	2.8	23
9	Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 2017, 377, 2240-2252.	27.0	557
10	Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk. <i>JAMA Cardiology</i> , 2017, 2, 837.	6.1	105
11	Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAf) in the US. <i>ClinicoEconomics and Outcomes Research</i> , 2016, 8, 215.	1.9	18
12	Cost-Effectiveness of Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis Versus Surgical ^o Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2016, 67, 29-38.	2.8	137
13	Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF ^o TIMI 48 trial. <i>American Heart Journal</i> , 2015, 170, 1140-1150.	2.7	26
14	Costs of Periprocedural Complications in Patients Treated With Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 829-836.	3.9	76
15	Costs and Cost-Effectiveness of Carotid Stenting Versus Endarterectomy for Patients at Standard Surgical Risk. <i>Stroke</i> , 2012, 43, 2408-2416.	2.0	63
16	Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Standard Care Among Inoperable Patients With Severe Aortic Stenosis. <i>Circulation</i> , 2012, 125, 1102-1109.	1.6	266